Brief: Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results, Provides Corporate Update
10/11/2022 22:16
Nov 10 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS PIVOTING STRATEGIC FOCUS REPORTS
THIRD
QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* NABRIVA THERAPEUTICS PLC - CASH RUNWAY EXTENDED INTO Q1
2023
* NABRIVA THERAPEUTICS PLC - Q3 2022 TOTAL REVENUE OF $9.2
MILLION
* NABRIVA THERAPEUTICS PLC - QTRLY LOSS PER SHARE OF $4.21
Source text for Eikon: ID:nGNXbrQb46
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update